Can you take ACE-031 and Kisspeptin-10 together?

There is no specific, well-documented interaction rule for combining ACE-031 and Kisspeptin-10 in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, ACE-031 or Kisspeptin-10?

ACE-031 is currently investigational (in trials) and Kisspeptin-10 is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

ACE-031 vs Kisspeptin-10

Q: What is the difference between ACE-031 and Kisspeptin-10?

ACE-031: Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks the primary signals that limit muscle growth by sequestering myostatin, activin, and related ligands before they reach cell surface receptors. Phase 2 trials in Duchenne muscular dystrophy demonstrated significant lean mass increases. Kisspeptin-10: Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

ACE-031

Investigational (in trials)

Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks the primary signals that limit muscle growth by sequestering myostatin, activin, and related ligands before they reach cell surface receptors. Phase 2 trials in Duchenne muscular dystrophy demonstrated significant lean mass increases.

Full profile

Kisspeptin-10

FDA-approved

Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.

Full profile

	ACE-031	Kisspeptin-10
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	ACVR2B-Fc, ActRIIB-Fc fusion protein	KP-10, Metastin(112-121), KISS1R agonist
Evidence	Investigational (in trials)	FDA-approved
Dosing range	0.3mg/kg–3mg/kg mg/kg, every 2–4 weeks (subcutaneous injection)	50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion)
Administration	Subcutaneous injection	Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses)
Key side effects	Nosebleeds (epistaxis — most common reported AE), Telangiectasia (visible small blood vessel dilation), Gum bleeding, Elevated hemoglobin	Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing
Cited sources	2 references	3 references

Key differences

Evidence level differs: ACE-031 is investigational (in trials), while Kisspeptin-10 is fda-approved.
Administration: ACE-031 — Subcutaneous injection; Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses).
Dosing units differ: ACE-031 is dosed in mg/kg, Kisspeptin-10 in mcg — they operate at different scales.
Frequency: ACE-031 is typically every 2–4 weeks (subcutaneous injection); Kisspeptin-10 is 1–2x daily (pulsatile administration is important — avoid continuous infusion).
Research depth: this profile cites 2 sources for ACE-031 vs 3 for Kisspeptin-10.

How each works

ACE-031

ACE-031 functions as a decoy receptor, binding myostatin, activin A/B, GDF-11, and BMP-9 in circulation before they can activate cellular ActRIIB receptors. In the Duchenne muscular dystrophy Phase 2 trial, ACE-031 produced meaningful lean body mass increases but was halted due to vascular side effects (epistaxis, telangiectasia) requiring dose and safety optimization.

Kisspeptin-10

Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.

Read the full ACE-031 profile Read the full Kisspeptin-10 profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.